Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 17 | 2023 | 2141 | 3.140 |
Why?
|
| Heart Transplantation | 7 | 2021 | 711 | 2.290 |
Why?
|
| Heart-Assist Devices | 6 | 2022 | 536 | 2.220 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 302 | 1.090 |
Why?
|
| Cardiology | 2 | 2020 | 260 | 1.020 |
Why?
|
| Patient Selection | 2 | 2020 | 658 | 1.020 |
Why?
|
| Registries | 5 | 2019 | 1873 | 0.860 |
Why?
|
| Hospice Care | 2 | 2023 | 198 | 0.840 |
Why?
|
| Stroke Volume | 4 | 2023 | 588 | 0.780 |
Why?
|
| Medicare | 3 | 2023 | 715 | 0.780 |
Why?
|
| Defibrillators, Implantable | 2 | 2016 | 297 | 0.780 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 152 | 0.720 |
Why?
|
| Home Care Services | 1 | 2023 | 244 | 0.690 |
Why?
|
| Waiting Lists | 2 | 2019 | 237 | 0.680 |
Why?
|
| BK Virus | 1 | 2019 | 13 | 0.670 |
Why?
|
| Population Health | 1 | 2020 | 45 | 0.650 |
Why?
|
| Patient Advocacy | 1 | 2019 | 73 | 0.620 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 195 | 0.620 |
Why?
|
| Viremia | 1 | 2019 | 130 | 0.620 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2016 | 45 | 0.600 |
Why?
|
| Triage | 1 | 2020 | 205 | 0.580 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 148 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 247 | 0.560 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2018 | 85 | 0.560 |
Why?
|
| Organizational Objectives | 1 | 2017 | 70 | 0.550 |
Why?
|
| Health Policy | 1 | 2020 | 351 | 0.550 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.540 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 109 | 0.530 |
Why?
|
| Heart Diseases | 1 | 2020 | 345 | 0.530 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2016 | 11 | 0.520 |
Why?
|
| Cardiovascular System | 1 | 2017 | 136 | 0.500 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 888 | 0.500 |
Why?
|
| Electric Countershock | 1 | 2016 | 105 | 0.500 |
Why?
|
| Mentors | 1 | 2017 | 178 | 0.490 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 337 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.480 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 410 | 0.480 |
Why?
|
| Mentoring | 1 | 2017 | 130 | 0.470 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2016 | 179 | 0.470 |
Why?
|
| Primary Prevention | 1 | 2016 | 186 | 0.460 |
Why?
|
| Health Services Research | 1 | 2017 | 389 | 0.450 |
Why?
|
| Quality Improvement | 2 | 2020 | 1093 | 0.410 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 374 | 0.380 |
Why?
|
| Medication Adherence | 1 | 2016 | 559 | 0.370 |
Why?
|
| Biomedical Research | 1 | 2017 | 632 | 0.370 |
Why?
|
| United States | 9 | 2023 | 13785 | 0.350 |
Why?
|
| Humans | 27 | 2023 | 128019 | 0.340 |
Why?
|
| Insurance, Health | 3 | 2021 | 267 | 0.330 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 7029 | 0.290 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 100 | 0.280 |
Why?
|
| Female | 15 | 2023 | 68016 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2020 | 10110 | 0.220 |
Why?
|
| Aged | 9 | 2023 | 21892 | 0.210 |
Why?
|
| Male | 13 | 2023 | 62757 | 0.210 |
Why?
|
| Risk Factors | 3 | 2023 | 9696 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1260 | 0.190 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 147 | 0.180 |
Why?
|
| Insurance Carriers | 1 | 2021 | 11 | 0.180 |
Why?
|
| Logistic Models | 2 | 2016 | 1975 | 0.180 |
Why?
|
| Pericarditis | 1 | 2020 | 11 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 14404 | 0.170 |
Why?
|
| Aftercare | 1 | 2022 | 206 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2703 | 0.170 |
Why?
|
| Cryptococcus neoformans | 1 | 2020 | 19 | 0.170 |
Why?
|
| Hospitalization | 2 | 2023 | 2057 | 0.170 |
Why?
|
| Cryptococcosis | 1 | 2020 | 25 | 0.170 |
Why?
|
| Cardiologists | 1 | 2020 | 45 | 0.170 |
Why?
|
| Patient Participation | 2 | 2021 | 409 | 0.170 |
Why?
|
| Hospices | 1 | 2021 | 89 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 4853 | 0.160 |
Why?
|
| Coronary Artery Bypass | 1 | 2021 | 222 | 0.160 |
Why?
|
| Adult | 8 | 2021 | 35176 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 260 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2020 | 3223 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 124 | 0.150 |
Why?
|
| Viral Load | 1 | 2019 | 449 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 64 | 0.140 |
Why?
|
| Community Health Services | 1 | 2019 | 226 | 0.140 |
Why?
|
| Long-Term Care | 1 | 2018 | 89 | 0.140 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 42 | 0.140 |
Why?
|
| Time Factors | 3 | 2016 | 6479 | 0.140 |
Why?
|
| Patient Safety | 1 | 2020 | 286 | 0.130 |
Why?
|
| Professional Competence | 1 | 2017 | 94 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2018 | 5378 | 0.130 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 77 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 185 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 15 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2022 | 850 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 579 | 0.130 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 45 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1408 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2021 | 466 | 0.120 |
Why?
|
| Career Choice | 1 | 2017 | 207 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 146 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 511 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 270 | 0.120 |
Why?
|
| Caregivers | 1 | 2022 | 810 | 0.120 |
Why?
|
| Propensity Score | 1 | 2016 | 264 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 198 | 0.120 |
Why?
|
| Physicians | 1 | 2023 | 858 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 675 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 567 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2016 | 235 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 366 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 851 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 710 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 238 | 0.110 |
Why?
|
| Survival Rate | 1 | 2018 | 1870 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1194 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1199 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1262 | 0.100 |
Why?
|
| Medicaid | 1 | 2017 | 433 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 1088 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 493 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1473 | 0.090 |
Why?
|
| Curriculum | 1 | 2017 | 909 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1492 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2016 | 663 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 3100 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2456 | 0.070 |
Why?
|
| Middle Aged | 6 | 2021 | 30812 | 0.070 |
Why?
|
| Exercise Test | 2 | 2021 | 613 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5353 | 0.060 |
Why?
|
| Focus Groups | 1 | 2023 | 452 | 0.040 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
|
| Fluconazole | 1 | 2020 | 17 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 88 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 2020 | 35 | 0.040 |
Why?
|
| Income | 1 | 2020 | 189 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 220 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 623 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2020 | 218 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 383 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 396 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 127 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 529 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 99 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 219 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1356 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1690 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 816 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 714 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 846 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 961 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 12281 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 860 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 688 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 20158 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 3766 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3874 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 7035 | 0.010 |
Why?
|